Last 12 months
Inside the activity.
0 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 12 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2022 Filed Mar 7, 2022 23:23 UTC |
Shah PriteshChief Commercial Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 38,027 | $80.59 Strike: $80.59 | $3,064,595.93 |
DisclosureSEC source: 0001645113-22-000020 · wf-form4_164669542266568.xml · derivative · entry 5 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,027 Underlying: Ordinary Shares · 38,027 shares Expires 2032-02-29 F3 · shares: Options to buy 38,027 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:23 UTC |
Shah PriteshChief Commercial Officer
|
SaleOrdinary Shares | 997 | $74.50 | $74,274.51 |
DisclosureSEC source: 0001645113-22-000020 · wf-form4_164669542266568.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,229 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:23 UTC |
Shah PriteshChief Commercial Officer
|
GrantOrdinary Shares | 21,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000020 · wf-form4_164669542266568.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,226 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 21, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:21 UTC |
DOYLE WILLIAM FDirector · Executive Chairman
|
GrantOptions to Buy Ordinary Shares · Derivative | 14,581 | $80.59 Strike: $80.59 | $1,175,082.79 |
DisclosureSEC source: 0001645113-22-000018 · wf-form4_164669525357817.xml · derivative · entry 1 DOYLE WILLIAM F · CIK 0001194459 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,581 Underlying: Ordinary Shares · 14,581 shares Expires 2032-02-29 F1 · shares: Options to buy 14,581 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:18 UTC |
Benaim ElyChief Medical Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 5,452 | $80.59 Strike: $80.59 | $439,376.68 |
DisclosureSEC source: 0001645113-22-000017 · wf-form4_164669511463233.xml · derivative · entry 5 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,452 Underlying: Ordinary Shares · 5,452 shares Expires 2032-02-29 F4 · shares: Options to buy 5,452 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:18 UTC |
Benaim ElyChief Medical Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 30,422 | $80.59 Strike: $80.59 | $2,451,708.98 |
DisclosureSEC source: 0001645113-22-000017 · wf-form4_164669511463233.xml · derivative · entry 4 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,422 Underlying: Ordinary Shares · 30,422 shares Expires 2032-02-29 F3 · shares: Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:18 UTC |
Benaim ElyChief Medical Officer
|
SaleOrdinary Shares | 803 | $74.50 | $59,821.89 |
DisclosureSEC source: 0001645113-22-000017 · wf-form4_164669511463233.xml · nonDerivative · entry 2 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,767 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:18 UTC |
Benaim ElyChief Medical Officer
|
GrantOrdinary Shares | 17,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000017 · wf-form4_164669511463233.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,570 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:16 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 7,664 | $80.59 Strike: $80.59 | $617,641.76 |
DisclosureSEC source: 0001645113-22-000015 · wf-form4_164669495236747.xml · derivative · entry 5 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,664 Underlying: Ordinary Shares · 7,664 shares Expires 2032-02-29 F4 · shares: Options to buy 7,664 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:16 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 38,390 | $80.59 Strike: $80.59 | $3,093,850.10 |
DisclosureSEC source: 0001645113-22-000015 · wf-form4_164669495236747.xml · derivative · entry 4 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,390 Underlying: Ordinary Shares · 38,390 shares Expires 2032-02-29 F3 · shares: Options to buy 38,390 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:16 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
SaleOrdinary Shares | 1,301 | $74.50 | $96,921.90 |
DisclosureSEC source: 0001645113-22-000015 · wf-form4_164669495236747.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,594 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:16 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
GrantOrdinary Shares | 21,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000015 · wf-form4_164669495236747.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,895 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:14 UTC |
Leonard Frank XChief Development Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 4,933 | $80.59 Strike: $80.59 | $397,550.47 |
DisclosureSEC source: 0001645113-22-000014 · wf-form4_164669485933981.xml · derivative · entry 5 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,933 Underlying: Ordinary Shares · 4,933 shares Expires 2032-02-29 F4 · shares: Options to buy 4,933 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023 and 2024, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:14 UTC |
Leonard Frank XChief Development Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 30,422 | $80.59 Strike: $80.59 | $2,451,708.98 |
DisclosureSEC source: 0001645113-22-000014 · wf-form4_164669485933981.xml · derivative · entry 4 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,422 Underlying: Ordinary Shares · 30,422 shares Expires 2032-02-29 F3 · shares: Options to buy 30,422 ordinary shares will vest and become exercisable in equal installments on each of March 1, 2023, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:14 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 930 | $74.50 | $69,283.14 |
DisclosureSEC source: 0001645113-22-000014 · wf-form4_164669485933981.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,594 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:14 UTC |
Leonard Frank XChief Development Officer
|
GrantOrdinary Shares | 17,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-22-000014 · wf-form4_164669485933981.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,524 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on each of March 1, 2023, 2024 and 2025, subject to the reporting person's continued employment through such dates. Read SEC document |
| March 03, 2022 Filed Mar 11, 2022 21:55 UTC |
Cordova AshleyChief Financial Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,200 | $11.46 Strike: $11.46 | $13,752.00 |
DisclosureSEC source: 0001645113-22-000032 · wf-form4_164703570445119.xml · derivative · entry 4 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,736 Underlying: Ordinary Shares · 1,200 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 03, 2022 Filed Mar 11, 2022 21:55 UTC |
Cordova AshleyChief Financial Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 3,840 | $15.60 Strike: $15.60 | $59,904.00 |
DisclosureSEC source: 0001645113-22-000032 · wf-form4_164703570445119.xml · derivative · entry 3 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,840 shares Expires 2025-04-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| March 03, 2022 Filed Mar 11, 2022 21:55 UTC |
Cordova AshleyChief Financial Officer
|
Exercise / conversionOrdinary Shares | 1,200 | $11.46 | $13,752.00 |
DisclosureSEC source: 0001645113-22-000032 · wf-form4_164703570445119.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,888 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2022 Filed Mar 11, 2022 21:55 UTC |
Cordova AshleyChief Financial Officer
|
Exercise / conversionOrdinary Shares | 3,840 | $15.60 | $59,904.00 |
DisclosureSEC source: 0001645113-22-000032 · wf-form4_164703570445119.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 17:39 UTC |
Burke William PatrickChief Human Resources Officer
|
GrantOrdinary Shares | 80 | $63.82 | $5,105.44 |
DisclosureSEC source: 0001645113-22-000007 · wf-form4_164202718179026.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,950 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 17:41 UTC |
Weinberg UriChief Science Officer
|
GrantOrdinary Shares | 35 | $63.82 | $2,233.63 |
DisclosureSEC source: 0001645113-22-000008 · wf-form4_164202724976066.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Science Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,815 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 22:38 UTC |
Benaim ElyChief Medical Officer
|
GrantOrdinary Shares | 55 | $63.82 | $3,509.99 |
DisclosureSEC source: 0001645113-22-000006 · wf-form4_164202710572487.xml · nonDerivative · entry 1 Benaim Ely · CIK 0001632237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,199 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 22:37 UTC |
Cordova AshleyChief Financial Officer
|
GrantOrdinary Shares | 46 | $63.82 | $2,935.63 |
DisclosureSEC source: 0001645113-22-000005 · wf-form4_164202703285939.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,804 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 22:31 UTC |
Danziger AsafDirector · Chief Executive Officer
|
GrantOrdinary Shares | 31 | $63.82 | $1,978.36 |
DisclosureSEC source: 0001645113-22-000004 · wf-form4_164202669529935.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,307 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 22:30 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
GrantOrdinary Shares | 75 | $63.82 | $4,786.35 |
DisclosureSEC source: 0001645113-22-000003 · wf-form4_164202660712829.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,974 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 20121 through December 31, 2021. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on December 31, 2021. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC |
Burke William PatrickChief Human Resources Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 1,402 | $0.00 Strike: $21.60 | $0.00 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · derivative · entry 9 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,098 Underlying: Ordinary Shares · 1,402 shares Expires 2027-10-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC |
Burke William PatrickChief Human Resources Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 9,750 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · derivative · entry 8 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 9,750 shares Expires 2027-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC |
Burke William PatrickChief Human Resources Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 17,452 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · derivative · entry 7 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 17,452 shares Expires 2026-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC |
Burke William PatrickChief Human Resources Officer
|
SaleOrdinary Shares | 399 | $76.03 | $30,335.97 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 6 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,870 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC |
Burke William PatrickChief Human Resources Officer
|
Exercise / conversionOrdinary Shares | 1,402 | $21.60 | $30,283.20 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 5 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC |
Burke William PatrickChief Human Resources Officer
|
SaleOrdinary Shares | 919 | $76.09 | $69,923.95 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 4 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,867 F2 · price: On January 3, 2022, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke, Mr. Burke sold 919 shares in multiple trades at prices ranging from $76.00 to $76.09. The price reported above reflects the weighted average sale price. Mr. Burke hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC |
Burke William PatrickChief Human Resources Officer
|
Exercise / conversionOrdinary Shares | 9,750 | $7.15 | $69,712.50 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 3 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,786 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC |
Burke William PatrickChief Human Resources Officer
|
SaleOrdinary Shares | 2,633 | $75.96 | $200,002.68 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 2 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,036 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:52 UTC |
Burke William PatrickChief Human Resources Officer
|
Exercise / conversionOrdinary Shares | 17,452 | $11.46 | $199,999.92 |
DisclosureSEC source: 0001645113-22-000001 · wf-form4_164141953630928.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Burke. Read SEC document |
| November 26, 2021 Filed Nov 29, 2021 21:48 UTC |
Danziger AsafDirector · Chief Executive Officer
|
PurchaseOrdinary Shares | 104 | $96.50 | $10,036.00 |
DisclosureSEC source: 0001645113-21-000116 · wf-form4_163822248140323.xml · nonDerivative · entry 3 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,276 Read SEC document |
| November 26, 2021 Filed Nov 29, 2021 21:48 UTC |
Danziger AsafDirector · Chief Executive Officer
|
PurchaseOrdinary Shares | 1,000 | $103.37 | $103,370.00 |
DisclosureSEC source: 0001645113-21-000116 · wf-form4_163822248140323.xml · nonDerivative · entry 2 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,172 Read SEC document |
| November 26, 2021 Filed Nov 29, 2021 21:48 UTC |
Danziger AsafDirector · Chief Executive Officer
|
PurchaseOrdinary Shares | 3,870 | $102.36 | $396,133.20 |
DisclosureSEC source: 0001645113-21-000116 · wf-form4_163822248140323.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,172 F1 · price: On November 26, 2021, Mr. Danziger purchased 3,870 shares in multiple trades at prices ranging from $102.00 to $102.60. The price reported above reflects the weighted average purchase price. Mr. Danziger hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 02, 2021 Filed Nov 3, 2021 20:11 UTC |
Cordova AshleyChief Financial Officer
|
SaleOrdinary Shares | 209 | $107.28 | $22,420.68 |
DisclosureSEC source: 0001645113-21-000114 · wf-form4_163597024160717.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,758 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:32 UTC |
Shah PriteshChief Commercial Officer
|
SaleOrdinary Shares | 30 | $140.18 | $4,205.40 |
DisclosureSEC source: 0001645113-21-000106 · wf-form4_163104675810103.xml · nonDerivative · entry 4 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,512 F4 · shares: Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Shah. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:32 UTC |
Shah PriteshChief Commercial Officer
|
SaleOrdinary Shares | 150 | $139.24 | $20,885.70 |
DisclosureSEC source: 0001645113-21-000106 · wf-form4_163104675810103.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,542 F3 · shares: On September 3, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 150 shares in multiple trades at prices ranging from $138.81 to $139.78. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 03, 2021 Filed Sep 7, 2021 20:32 UTC |
Shah PriteshChief Commercial Officer
|
SaleOrdinary Shares | 321 | $138.27 | $44,385.63 |
DisclosureSEC source: 0001645113-21-000106 · wf-form4_163104675810103.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,692 F2 · shares: On September 3, 2021, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Shah, Mr. Shah sold 321 shares in multiple trades at prices ranging from $137.75 to $138.56. The price reported above reflects the weighted average sale price. Mr. Shah hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:39 UTC |
Leonard Frank XChief Development Officer
|
SaleOrdinary Shares | 540 | $138.23 | $74,645.28 |
DisclosureSEC source: 0001645113-21-000109 · wf-form4_163104715467852.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,153 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:37 UTC |
Cordova AshleyChief Financial Officer
|
SaleOrdinary Shares | 828 | $138.23 | $114,456.10 |
DisclosureSEC source: 0001645113-21-000108 · wf-form4_163104705924754.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,967 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Amended total to correct prior mathematical error. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:35 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
SaleOrdinary Shares | 181 | $138.23 | $25,019.99 |
DisclosureSEC source: 0001645113-21-000107 · wf-form4_163104692257841.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,899 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 20:32 UTC |
Shah PriteshChief Commercial Officer
|
SaleOrdinary Shares | 156 | $138.23 | $21,564.19 |
DisclosureSEC source: 0001645113-21-000106 · wf-form4_163104675810103.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,013 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC |
Cordova AshleyChief Financial Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 2,606 | $0.00 Strike: $69.37 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 18 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,375 Underlying: Ordinary Shares · 2,606 shares Expires 2030-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC |
Cordova AshleyChief Financial Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,298 | $0.00 Strike: $47.04 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 17 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 Underlying: Ordinary Shares · 7,298 shares Expires 2029-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC |
Cordova AshleyChief Financial Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 2,767 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 16 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,533 Underlying: Ordinary Shares · 2,767 shares Expires 2028-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 20:40 UTC |
Cordova AshleyChief Financial Officer
|
Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 8,026 | $0.00 Strike: $21.50 | $0.00 |
DisclosureSEC source: 0001645113-21-000103 · wf-form4_162914638367403.xml · derivative · entry 15 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,297 Underlying: Ordinary Shares · 8,026 shares Expires 2028-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.